Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus DISPERMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus DISPERMOX.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs DISPERMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
None Documented
None Documented
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic